Drug-induced QT prolongation

Global Oral Solid Dosage Manufacturing Market to 2035: by Type of Finished Dosage Form, Type of Packaging, Scale of Operation, Company Size, Therapeutic Area and Key Geographical Regions - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 11, 2023
Health, Pharmaceutical, Drug-induced QT prolongation, Tablet, API, Capsule, USD, ODT, Catalent, CMIC, OSD, Recipharm, Solubility, Micro Labs, Pharmaceutical industry, Fine chemical, Vaccine

Question 1: What is the global market size of oral solid dosage manufacturing market?

Key Points: 
  • Question 1: What is the global market size of oral solid dosage manufacturing market?
  • Question 5: Which region has the highest market share in the oral solid dosage contract manufacturing market?
  • Question 6: What are the leading market segments in the oral solid dosage contract manufacturing market?
  • Question 9: What are the current initiatives undertaken by big pharma players engaged in the oral solid dosage contract manufacturing market?

Basking Biosciences to Present Clinical Trial Results on First Reversible Thrombolytic Agent at American Heart Association International Stroke Conference 2023

Retrieved on: 
Tuesday, January 31, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, American Heart, Von Willebrand factor, Blood, RNA, University, Drug-induced QT prolongation, ISC, Safety, University of Pittsburgh, Bleeding, Conference, Thrombolysis, Doctor of Philosophy, Pharmaceutical industry, Stroke, Pharmacokinetics, Tolerability

Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC).

Key Points: 
  • Basking Biosciences, a clinical-stage biopharmaceutical company developing the first reversible thrombolytic therapeutic for ischemic stroke, today announced the company will be presenting three oral presentations and two moderated posters concerning the company’s novel drug candidate at the American Heart Association’s 2023 International Stroke Conference (ISC).
  • The ISC is being held both live and virtually from February 8-10 in Dallas, Texas.
  • “Current drug treatments for acute ischemic stroke have been restricted by a narrow therapeutic window and high risk of bleeding.
  • It is a rapid-onset, short-acting thrombolytic agent that is capable of recanalizing blocked blood vessels within a greatly extended therapeutic window than current therapy.”

Biotricity’s Real-Time Monitoring Bioflux Device can Help Identify Life Threatening QT Prolongation in COVID-19 Patients

Retrieved on: 
Tuesday, April 7, 2020
Branches of biology, Cardiac arrhythmia, Computer programming, RTT, Software, Channelopathies, Long QT syndrome, Syndromes affecting the heart, Sulpiride, QT, Drug-induced QT prolongation, QT interval

One of the key features that Bioflux has is the ability to record QT variability and ranges.

Key Points: 
  • One of the key features that Bioflux has is the ability to record QT variability and ranges.
  • This is particularly important since a known side effect of many drugs is QT prolongation which can lead to very serious arrhythmias.
  • Drugs that are currently being studied to treat COVID-19 patients, such as hydroxychloroquine, have been known to cause QT prolongation.
  • Our practice has been utilizing this aspect of the Bioflux as QT prolongation can be a side effect of many drugs.

The Cardiac Risk of Chloroquine in Unapproved Indications

Retrieved on: 
Friday, March 27, 2020
RTT, Antimalarial medication, QT interval, Branches of biology, Chloroquine, Magnesium deficiency, QTC, Chemistry, Biology, Torsades de pointes, Drug-induced QT prolongation

Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.

Key Points: 
  • Recently, the unapproved use of the antimalarial drug, chloroquine, has been touted as a treatment for COVID-19 with some reported deaths with its use in afflicted patients.
  • Because the QT interval is influenced by heart rate, it is most often given as the corrected QT interval or QTc.
  • Even therapeutic doses of chloroquine in healthy patients are associated with prolongation of QTc1, although this is generally well tolerated.
  • This is why chloroquine has specific warnings in its labeling to inform of the potential danger in patients with underlying risk factors (cardiac disease, hypokalemia, hypomagnesemia, bradycardia)3.